Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06269705 · ClinicalTrials.gov registry record · Phase 3
ZILRETTA in Subjects With Shoulder Osteoarthritis
A Phase 3 study of Glenohumeral Osteoarthritis, sponsored by Pacira Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06269705: Recruiting Phase 3 study of Glenohumeral Osteoarthritis, sponsored by Pacira Pharmaceuticals.
NCT06269705 is a Phase 3 study of Glenohumeral Osteoarthritis that is actively recruiting participants, run by Pacira Pharmaceuticals. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06269705, a Phase 3 study of Glenohumeral Osteoarthritis, is actively recruiting participants, sponsored by Pacira Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo
Conditions Studied
Interventions
- OTHER Placebo
- DRUG ZILRETTA
Study Locations (20)
Florida
- Orthopedic Center of Palm Beach City - Atlantis
- Baptist Health Orthopedic Care - Miami Gardens - Maimi
- Infinite Clinical Research - Miami
- Gulfcoast Research Institute - Sarasota
- Clinical Research of West Florida - Tampa
- Hospital for Special Services - West Palm Beach
California
- Horizon Clinical Research - La Mesa
- Napa Pain Institute - Napa
- Stanford University - Sports Medicine Clinic - Redwood City
Arizona
- Onyx Clinical Research - Surprise
- Tucson Orthopaedic Institute (TOI) - East Office - Tucson
Alabama
- Alabama Orthopaedic Center- Research - Vestavia Hills
District of Columbia
- International Spine, Pain & Performance Center - Washington D.C.
Idaho
- Injury Care Research - Boise
Kansas
- Kansas City Bone & Joint Clinic - Overland Park - Overland Park
Louisiana
- Ochsner Sports Medicine Institute - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What NCT06269705 shows while recruiting
NCT06269705 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Glenohumeral Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06269705 names 20 study sites across 12 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06269705 about?
NCT06269705 is a clinical study titled "ZILRETTA in Subjects With Shoulder Osteoarthritis". Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with...
What is the current status of trial NCT06269705?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-02-05. Estimated completion is 2026-08.
What conditions does trial NCT06269705 study?
This clinical trial studies the following conditions: Glenohumeral Osteoarthritis.
What interventions are being tested in trial NCT06269705?
The interventions under investigation include: Placebo (OTHER), ZILRETTA (DRUG).
Who is sponsoring clinical trial NCT06269705?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06269705 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06269705's enrollment target sits among peer trials
150 1520th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI